Related Experiment Video
Updated: Mar 11, 2026
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
Selective Pressure-Regulated Retroinfusion for Gene Therapy Application in Ischemic Heart Disease
Rabea Hinkel1,2,3, Christian Kupatt4,5
1Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, TU Munich, Ismaningerstr. 22, 81675, Munich, Germany. rabea.hinkel@tum.de.
Insights
Gene therapy for heart failure shows promise. Selective pressure-regulated retroinfusion via coronary veins offers a safer, more effective delivery method than traditional routes.
Area of Science:
- Cardiovascular Medicine
- Gene Therapy
- Regenerative Medicine
Background:
- Coronary heart disease remains a leading cause of death, often leading to chronic heart failure despite advanced treatments.
- Heart failure is characterized by adverse cardiac remodeling, including cardiomyocyte hypertrophy, fibrosis, and capillary rarefaction.
- Gene therapy presents a promising avenue for treating heart failure by modulating contractile function or promoting therapeutic neovascularization.
Purpose of the Study:
- To evaluate the efficacy and safety of different gene delivery routes for cardiac gene therapy.
- To identify an optimal application route that enhances transduction efficacy in the target area while minimizing off-target effects.
- To explore the potential of retrograde coronary vein delivery for gene therapy in the context of ischemic heart disease.
Main Methods:
- Comparison of systemic versus regional intra-coronary application routes for gene therapy.
- Investigation of antegrade delivery challenges due to coronary artery stenosis or occlusion.
- Assessment of coronary veins as an alternative, unaffected pathway for retrograde gene delivery.
- Development and evaluation of selective pressure-regulated retroinfusion (SSR) for enhanced safety and efficacy.
Main Results:
- Regional intra-coronary application offers higher transduction efficacy and reduced off-target contamination compared to systemic delivery.
- Antegrade delivery can be compromised by coronary artery disease.
- Coronary veins are not affected by typical coronary artery disease, making them a viable route.
- Selective pressure-regulated retroinfusion (SSR) enhances safety by preventing coronary vein injury and improves targeted gene delivery.
Conclusions:
- Retrograde delivery via coronary veins, specifically using selective pressure-regulated retroinfusion (SSR), is a favorable approach for cardiac gene therapy.
- SSR facilitates efficient gene transduction in the target cardiac region while minimizing systemic exposure and potential complications.
- This method holds significant potential for improving therapeutic outcomes in patients with heart failure due to ischemic heart disease.
Abstract:
Coronary heart disease is still the leading cause of death in industrialized nations. Even though revascularization strategies such as coronary artery bypass graft surgery, percutaneous coronary intervention and enhanced drug therapy significantly improved the outcome, about 30 % of patients develop chronic heart failure. Ischemic heart disease and heart failure are characterized by an adverse remodeling of the heart, featuring cardiomyocyte hypertrophy, increased fibrosis and capillary rarefaction. Therefore, gene therapeutic approaches for the treatment of heart failure, such as the modulating contractile function or therapeutic neovascularization, seem to be promising. To achieve an efficient transduction of the gene therapeutic agent, the time point and the application route seem to be important for the therapeutic success. In contrast to the classical systemic application regional intra-coronary application offers the possibility of higher transduction efficacy in the target area accompanied by a reduced off-target contamination. Antegrade delivery however, may be impaired by coronary heart disease, such as stenosis or occlusion of a coronary artery. Coronary veins appear not to be affected and might therefore be the preferable application route for gene therapy. For an effective and safe retrograde application in gene therapy, selective catheterization of the coronary vein draining the target area is necessary. In addition, to avoid coronary vein injury, a pressure regulated infusion enhances safety. Therefore, a selective pressure regulation of retroinfusion (SSR) seems to be a favorable approach for gene therapy transduction in combination with reduced systemic contamination.
